Cobimetinib - Genentech

Drug Profile

Cobimetinib - Genentech

Alternative Names: Cobimetinib fumarate; Cotellic; GDC-0973; RG-7421; RO 5514041; XL-518

Latest Information Update: 24 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Exelixis
  • Developer Bristol-Myers Squibb; Exelixis; Genentech; M. D. Anderson Cancer Center; Massachusetts General Hospital; Memorial Sloan-Kettering Cancer Center; Roche; University Hospital Tubingen
  • Class Antineoplastics; Azetidines; Fluorobenzenes; Iodobenzenes; Small molecules
  • Mechanism of Action Mitogen-activated protein kinase kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Malignant melanoma
  • Phase III Colorectal cancer
  • Phase II Breast cancer; Head and neck cancer; Histiocytosis; Renal cell carcinoma; Urogenital cancer
  • Phase I/II Multiple myeloma; Non-small cell lung cancer; Pancreatic cancer; Solid tumours

Most Recent Events

  • 20 Jan 2018 Updated efficacy and adverse events data from a phase Ib trial in Colorectal cancer presented at the 2018 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO-GCS-2018)
  • 17 Nov 2017 Roche plans a phase I/II trial for Non-small cell lung cancer (Combination therapy, Metastatic disease) in Australia, South Korea, France, Spain, United Kingdom and USA in December 2017 (NCT03337698)
  • 17 Nov 2017 Phase I development in Solid tumours (Combination therapy, Late-stage disease) in is ongoing in USA, Singapore, South Korea, Germany, Canada, Australia and Spain (NCT01988896)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top